Previous 10 | Next 10 |
HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B vi...
Image Source: World Health Organization Company Thesis Spring Bank Pharmaceuticals' ( SBPH ) $10 million enterprise value remains deceptively cheap for value investors for a reason: its sole Phase 2 candidate for the treatment of HBV is likely inferior when evaluated against competitor...
HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has initia...
HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Drisco...
Spring Bank Pharma (NASDAQ: SBPH ): Q3 GAAP EPS of -$0.42 beats by $0.19 . More news on: Spring Bank Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOPKINTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial resu...
Spring Bank Pharmaceuticals (NASDAQ: SBPH ) is up 4.6% in thin postmarket trading after a shareholder filed to offer up to 2.58M shares . More news on: Spring Bank Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
7 of 30 patients were HBsAg responders with ≥ 0.5log₁₀ reduction Inarigivir 50mg plus Vemlidy® 25mg was generally safe and well tolerated at 12 weeks Evaluation of inarigivir 200mg and 400mg co-administered with Vemlidy is ongoing HOPKINTON, Mass., Oct...
HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Drisc...
HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Dr. Thomas H...
News, Short Squeeze, Breakout and More Instantly...
Spring Bank Company Name:
SBPH Stock Symbol:
NASDAQ Market:
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals To Commence Trading November 23 on Nasdaq: FSTX PR Newswire CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 CAMBRIDGE, England and CAMBRIDGE, Mass. , Nov. 20, 2020 /PRN...
CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics 1-for-4 Reverse Stock Split to be Effective November 23, 2020 PR Newswire HOPKINTON, Mass., Nov. 20, 2020 HOPKINTON, Mass. , Nov. 20, 2020 /PRNe...
HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stock...